TABLE 5.
Correlation between patient genotypes and response to antipsychotics.
| GENE | SNP | Genotype | Responders (N) | Non-responders (N) | P | Odds ratio (95% C.I.) |
|---|---|---|---|---|---|---|
| ATP1A2 | rs6688363 | C/C | 157 | 146 | 0,17 a | 0.84 (0.6–1.2) |
| C/T | 76 | 56 | ||||
| T/T | 16 | 10 | ||||
| SPOPL | rs10170310 | A/A | 184 | 145 | 0,08 a | 1.3 (0.9–1.9) |
| A/G | 62 | 58 | ||||
| G/G | 3 | 9 | ||||
| GRM7 | rs2133450 | A/A | 62 | 64 | 0,06 a | 0.6 (0.5–1.5) |
| A/C | 118 | 105 | ||||
| C/C | 69 | 43 | ||||
| Intergenic | rs10023464 | C/C | 207 | 188 | 0,07 a | 0.6 (0.4–1.1) |
| C/T | 38 | 23 | ||||
| T/T | 4 | 1 | ||||
| Intergenic | rs7668556 | T/T | 78 | 80 | 0,06 a | 0.75 (0.5–1.1) |
| T/A | 120 | 101 | ||||
| A/A | 51 | 31 | ||||
| GRID2 | rs1875705 | A/A | 82 | 61 | 0,35 a | (0.8–1.8) |
| A/G | 118 | 105 | ||||
| G/G | 49 | 46 | ||||
| PDE4D | rs17382202 | C/C | 160 | 134 | 0,89 a | 0.9 (0.6–1.4) |
| C/T | 80 | 71 | ||||
| T/T | 9 | 7 | ||||
| CYP2C19 | rs12767583 | C/C | 171 | 155 | 0,17 a | 0.8 (0.5–1.2) |
| C/T | 69 | 54 | ||||
| T/T | 9 | 3 | ||||
| Intergenic | rs7395555 | G/G | 156 | 145 | 0,20 b | 0.8 (0.5–1.1) |
| G/C | 88 | 59 | ||||
| C/C | 5 | 8 | ||||
| TJP1 | rs711355 | C/C | 96 | 84 | 0,85 b | 0.9 (0.6–1.4) |
| C/T | 114 | 94 | ||||
| T/T | 39 | 34 | ||||
| TNFRSF11A | rs2980976 | G/G | 175 | 151 | 0,84 b | 0.9 (0.6–1.4) |
| G/A | 69 | 55 | ||||
| A/A | 5 | 6 |
ATP1A2, Sodium/potassium-transporting ATPase subunit alpha-2; SPOPL, Speckle Type BTB/POZ Protein Like; GRM7, Metabotropic glutamate receptor 7; GRID2, Glutamate Ionotropic Receptor Delta Type Subunit 2; PDE4D, Phosphodiesterase 4D; CYP2C19, Cytochrome P450 Family 2 Subfamily C Member 19; TJP1, Tight Junction Protein 1; TNFRSF11A, TNF Receptor Superfamily Member 11A. P p-value, trends towards significance are in italics.
a
= χ2-test for trend.
b
= Fisher exact test.